Index

Note: Figures and Tables are indicated by italic page numbers, and Boxes by emboldened numbers

abdominal circumference, measurement in diabetic pregnancy, 223, 226
abdominal pain (symptom), in children, 32, 196
Aberdeen Maternity Hospital, combined diabetic antenatal charts, 224–225
acarbose, nocturnal hypoglycaemia affected by, 94
ACE, serum levels and risk of severe hypoglycaemia, 70–71, 174, 201
ACE inhibitors, and severe hypoglycaemia, 71
acetazolamide, 133
acquired hypoglycaemia syndromes, and risk of severe hypoglycaemia, 68–70
activity holidays, 316
Addison’s disease, 74, 102, 130, 206
and dangerous driving charge, 322, 328
adipose tissue, metabolic pathways, 2, 3, 4, 5
ADOPT (A Diabetes Outcome Progression Trial), 247
adrenal system, hormonal changes during hypoglycaemia, 13, 15, 21, 129, 142
adrenaline, see epinephrine
adrenocorticotrophic hormone (ACTH), changes during hypoglycaemia, 13, 14
aerobic exercise, 314
ageing
blood glucose thresholds affected by, 239, 241
counterregulatory responses affected by, 241–242
symptoms of hypoglycaemia affected by, 239–240
aggressiveness (symptom), 32, 32, 33, 196, 312
mistaken for alcohol inebriation, 328
air traffic controllers, 324
air travel, 323
airline pilots, 323, 324
alanine, as glucose precursor, 2, 124, 125
alcohol consumption
advice on, 108
biochemical effects, 104–105
and hypoglycaemia, 7, 62, 75, 103–109, 131, 328
in type 2 diabetes, 246
alcohol intoxication
brain damage due to, 293
death due to, 272
hypoglycaemic symptoms mistaken for, 62, 103, 318, 327–328
aldostrone, changes during hypoglycaemia, 15
alpha-glucosidase inhibitors, 247
American Diabetes Association, on blood glucose lower limit, 173
amino acids, as glucose precursors, 2, 124, 125
anaerobic exercise, 313–314
analogue insulins, see insulin analogues
angina, 278
angiotensin-converting enzyme (ACE) activity, risk of severe hypoglycaemia affected by, 70–71, 174, 201
angiotensin, changes during hypoglycaemia, 15
anger feelings during hypoglycaemia, 43, 312, 328
antecedent hypoglycaemia
autonomic responses affected by, 159, 173
cognitive dysfunction affected by, 41, 159
counterregulatory response affected by, 129, 156–161
and impaired awareness of hypoglycaemia, 160
subsequent hypoglycaemia affected by, 35, 41, 156–161
antecedent nocturnal hypoglycaemia
caffeine-associated reduction, 110
cause of impaired awareness of hypoglycaemia, 88–89, 160, 166
effects, 157, 160

© 2007 John Wiley & Sons, Ltd
anterior pituitary gland, hormonal changes during hypoglycaemia, 13–14, 13
anxiety about hypoglycaemia, 44, 49, 172, 310–311, 312
and counterregulatory deficiencies, 135
as warning symptom, 26, 30, 31, 240
argumentativeness (symptom), in children, 32
armed forces, employment in, 324
asymptomatic hypoglycaemia definition, 50, 51
frequency, 55–57, 145
and impaired awareness of hypoglycaemia, 154–155
atrial fibrillation, 277
auditory processing, effect of hypoglycaemia, 42
automatism, 318
autonomic dysfunction, and impaired awareness of hypoglycaemia, 110, 152–153
autonomic nervous system, 10, 11
activation during hypoglycaemia, 10–12, 21
autonomic neuropathy
blood glucose threshold(s), 151
death due to, 272–273, 275, 276
and impaired awareness of hypoglycaemia, 152–153
autonomic symptoms, 30, 31, 142, 143, 196
blood glucose threshold(s), 29, 50, 142, 151, 173
in children, 32, 196, 327
compared with neuroglycopenic symptoms, 144
and detection of hypoglycaemia, 35, 142–143
in exam situations, 327
in older people, 240
awareness of hypoglycaemia, 142–145, see also impaired awareness of hypoglycaemia
classification of, 146–147
enhancement by caffeine, 110
external cues, 145
factors influencing, 144
internal cues, 36, 142–144, 145

behavioural disturbance (symptom), in children, 32, 33, 43
beta-adrenergic sensitivity, effect of impaired awareness of hypoglycaemia, 153
beta-agonists, nocturnal hypoglycaemia affected by, 94
beta-endorphins, changes during hypoglycaemia, 13, 14
beverages, hypoglycaemia treatment using, 114, 208
biochemical definitions (of hypoglycaemia), 49–50, 192
Blood Glucose Awareness Training (BGAT) programme, 34, 164
blood glucose monitoring
detection of asymptomatic hypoglycaemia by, 51, 113–114, 121–122, 145, 182
for impaired awareness patients, 164
practical problems, 182
target ranges, 184, 223
training in use, 182–183
unwillingness to do, 184
workplace, 326
blood glucose thresholds
autonomic responses, 29, 50, 142, 151, 173, 196
cognitive dysfunction, 37, 38, 39, 41, 50, 142, 159, 173
counterregulatory responses, 9, 50, 126, 134, 142, 152
effect of antecedent hypoglycaemia, 159
Diabetes UK recommendation, 50, 114, 173, 192
driving performance deterioration, 318
effect of age, 239, 241
neurophysiological dysfunction, 50, 142
nocturnal hypoglycaemia, 84, 85
severe neuroglycopenia, 142
warning symptoms, 29, 50, 142, 149–152, 196
effect of antecedent hypoglycaemia, 159, 173
effect of strict glycaemic control, 41, 50, 150, 152, 155
blood glucose variability, and risk of hypoglycaemia, in type 2 diabetes, 246
blood pressure, changes due to hypoglycaemia, 16, 276, 277
blood-to-brain glucose transport, 6, 133, 155
brain
counterregulatory responses, 124, 125–126
effects of glucose deprivation on metabolism, 5–7
regional variation, 6, 179
reversible effects of hypoglycaemia, 290
structural changes, 294
hypoglycaemia-associated, 296–301
INDEX

brain damage
  causes, 6, 116, 203, 205, 273, 285, 293
deaths due to, 268, 270
brain fuel, 5, 6, 191, 203
  transport mechanism, 6, 132
  and counterregulatory response failure, 132–133
brain glycogen supercompensation hypothesis, 133
brain injury, hypoglycaemia-induced, 301–302
  alteration due to hypoglycaemia, 133, 176
  children, 191, 192, 202
‘brittle’ diabetes, 130, 136
  Bucharest-Dusseldorf Study, 65, 66
  bus drivers, 323, 326, 329

C-peptide negativity, and risk of severe hypoglycaemia, 72, 174
caffeine
  enhancement of hypoglycaemia awareness by, 110, 163–164
  pharmacological actions, 109, 133, 134, 162
  sleep pattern affected by, 111
  symptoms intensity affected by, 35, 110–111
  carbohydrate/insulin mismatch, 62, 101
cardiac arrhythmias
  and coronary heart disease, 276–278
  death due to, 272
  and hypoglycaemia, 273–276
cardiovascular disease, effect of hypoglycaemia, 276–279

catecholamines
  changes during hypoglycaemia, 8, 9, 13, 15
  effect of alcohol, 106, 107, 108
causes of hypoglycaemia, 7, 61–63, 102
  alcohol consumption, 62, 103–109
  patient error, 62, 103
central nervous system (CNS)
  action of insulin on, 125–126
  effects of glucose deprivation on metabolism, 5–7
  structural changes in diabetes, 294
cerebral adaptation, 6, 41, 151, 155, 177–179
cerebral atrophy, 295, 297, 298, 299, 300
  prevalence with increasing age, 298
  changes during hypoglycaemia, 16, 17, 160, 294–296
cerebral glucose sensors, 10, 13, 177
cerebral glycogen metabolism, 133, 301
cerebral oedema, 116, 293
cerebral trauma, children, 204–205
childhood hypoglycaemia
  cognitive impairment caused by, 204–206, 234, 286–287
  long-term effects, 204–205
  short-term effects, 204
  consequences, 204–207
Nocturnal, 83–85, 197, 203–206
  preventative management of, 206–208
risk factors, 197–202
  age, 200
  clinic structure/size, 201
  diet, 199
  genetics, 201
  intensive insulin therapy, 198–199
  physical activity, 200–201, 315
  sleep, 198
  strict glycaemic control, 197–198
children
  counterregulatory responses, 133–134, 202–203
  definition of hypoglycaemia, 191–193
  learning ability affected by hypoglycaemia, 203
  sporting activities, 200–201, 317
  and strict glycaemic control, 185, 205
  symptoms of hypoglycaemia, 32–33, 196–197
chlorpropamide, 247, 249, 251
choice/decision reaction time, effect of hypoglycaemia, 38, 39, 179, 203
clinical definitions (of hypoglycaemia), 50–51, 112–114, 172–173
cognitive dysfunction
  blood glucose thresholds, 37, 38, 39, 41, 142, 159, 173
  factors affecting, 40–41, 103, 161
  hypoglycaemia-induced, 37–43
  in children and infants, 202–204, 232, 286–287, 326, 327
  in examinations [academic], 326, 327
  and nocturnal hypoglycaemia, 89, 204
  real-life implications, 41–43
cold-induced hypoglycaemia, 316
college examinations, 326–327
colleges, emergency treatment arrangements, 326
complications due to diabetes, see also microvascular complications in pregnancy, 230–234
risks to fetus/infant, 231–233
risks to mother, 230–232
concentration difficulty (symptom), 26, 27, 29, 30, 31, 36, 143
children, 196, 327
older people, 239
in pregnancy, 220
confusion (symptom), 26, 27, 31, 36, 196
in older people, 239
congenital malformations
incidence in diabetic pregnancy, 221
reduction of risks, 229, 232
continuous glucose monitoring systems (CGMS), 57, 112–114
exercise in childhood study, 200
hypoglycaemia defined, 113
limitations, 113, 114
nocturnal hypoglycaemia studied, 85, 114, 219
treatment of counterregulatory failure, 135
use in detection of (asymptomatic) hypoglycaemia, 113–114, 145, 183, 245
continuous subcutaneous insulin infusion (CSII) compared with multiple injection therapy, 181, 182
adolescents, 208
in type 2 diabetes, 254–255
and exercise, 200, 314
exercise in childhood study, 200
and nocturnal hypoglycaemia, 95, 228
and severe hypoglycaemia, 65, 174, 180, 181
in children and adolescents, 208
treatment of counterregulatory failure, 135
convulsions, 290–293
coordination, lack of (symptom), 26, 29, 30, 31, 196
in older people, 239
cornstarch, nocturnal hypoglycaemia affected by, 93, 208
coronary heart disease, and cardiac arrhythmias, 276–278
cortical atrophy, 297, 299, 300
cortisol
responses during hypoglycaemia, 9, 13, 15, 130
in children, 202
defects, 130–131
effect of alcohol, 104, 107
counterregulatory responses, 7–10, 21, 123–126
age-related changes, 241–242
blood glucose threshold(s) for, 9, 50, 126, 134, 142, 152
effect of age, 240, 241
defective, 126–133
causes, 127–128, 129, 131
effect of intensive insulin therapy, 174–175
mechanisms, 131–134
in pregnant women, 221, 222
risk factors, 127, 173
and severe hypoglycaemia, 69
treatment of, 135
effect of alcohol, 62, 103, 105–106
effect of exercise, 63, 313
effect of posture, 87
and nocturnal hypoglycaemia, 86–88, 202
children, 202
normal, 7–10, 123–126
stimulus for, 9, 124–125, 177
principal metabolic effects, 124–125
suppression during sleep, 73, 87–88, 202
in type 2 diabetes, 242–245
cross-sectional studies
impaired awareness of hyperglycaemia, 147, 148
severe hypoglycaemia, children, 193, 194, 286
dangerous activities/sports, 315, 316
dangerous driving offence, 322
dangerous jobs dealing with, 185
restrictions, 324
‘dawn phenomenon’, 91, 198
‘dead in bed’ syndrome, 83, 89, 265, 269–271, 273
possible risk factors, 273
deaths due to hypoglycaemia, see also sudden death
certification, 266
estimates of incidence, 267
post-mortem diagnosis, 266–267
risk factors, 267–268
decision reaction time, effect of hypoglycaemia, 38, 39, 203
definitions (of hypoglycaemia), 49–51, 112–114, 172–173
children, 191–193
detection of (asymptomatic) hypoglycaemia, 51, 113–114, 121–122, 145, 182
dextrose (glucose) intravenous solution, 115–116

Diabetes Control and Complications Trial (DCCT)
  children, severe hypoglycaemia, 194, 197
cognitive function affected by hypoglycaemia, 289
complications of type 1 diabetes, 49, 63
definition of severe hypoglycaemia, 51
HbA\textsubscript{1c} as risk factor for severe hypoglycaemia, 67–68, 121
hypoglycaemia in pregnancy, 217
intensive compared with conventional insulin therapy, 65, 66, 172
  in pregnant women, 226–227, 228
nocturnal hypoglycaemia, 73
risk factors examined, 64
subjects in trial, 52, 65, 302
vascular complications reduced, 183

Diabetes in Early Pregnancy (DIEP) study, 219

Diabetes UK
  on blood glucose lower limit, 50, 114, 173, 191
  on sudden unexpected deaths, 268
diabetic encephalopathy, 285, 302–303
diabetic ketoacidosis (DKA)
  deaths due to, 267, 269, 270
  as side effect of intensive insulin therapy, 179
worry about, 205
diabetic pregnancy, see also pregnancy
  clinical management in, 223–229
  combined diabetic antenatal charts, 224–225
counterregulatory responses, 221, 222
frequency of hypoglycaemia, 217–220
insulin regimens in, 226–229
management of delivery, 230
reasons for greater risk of hypoglycaemia, 220–222
timing of delivery, 230
diet, as risk factor in children, 199
dietary advice/intervention
  in diabetic pregnancy, 228
  in nocturnal hypoglycaemia, 92–94, 208
dipeptidyl peptidase IV (DPP-IV) inhibitors, 255
disobedience (symptom), in children, 33, 312
dizziness (symptom), 26, 27, 29
  children, 32, 196
  older people, 240
Dose Adjustment For Normal Eating (DAFNE) trial, 172
doses of insulin, effects on hypoglycaemic risk, 73
Driver and Vehicle Licensing Agency (DVLA), notifications, 319
driving
  advice for diabetic drivers, 320–322
  advice on alcohol consumption, 108
effect of hypoglycaemia, 41–42, 231, 318
  and risk of accidents, 318–319
medico-legal aspects, 322
by pregnant women, 231
reasons to cease, 321
driving licences
  restriction of, 318
  vocational, 320
drowsiness (symptom), 26, 30, 31, 196
children, 32, 196, 196, 327
difficulty in interpreting, 144
older people, 240
drug, insulin [treated in law] as, 321–322
duration of insulin therapy
  and defective responses to hypoglycaemia, 131, 132
  and mild hypoglycaemia 55
impairment awareness of hypoglycaemia affected by, 69, 147, 148
as risk factor for severe hypoglycaemia, 64, 68, 69–70, 102
type 2 diabetes, 252, 253, 254
early-warning symptoms, 27, 29, 30, 144
actions taken by patient, 114
Edinburgh Hypoglycaemia Scale, 37
  symptom groupings and classification, 30, 31
education/training programmes, 34, 66, 67, 121, 122, 135, 183
  for children, 207–208
elderly people, see older people
electrocardiogram (ECG), QT interval measurements, 274, 275
electroencephalograms (EEG)
  children with diabetes, 287, 292
  limitations in diagnosing convulsions, 295
emergency services
  employment, 320, 324
  and severe hypoglycaemia, 58, 60, 115–116
  type 1 compared with type 2 diabetes, 255
emotions during hypoglycaemia, 43–44, 312–313
employment aspects, 323–326
restricted jobs [listed], 324
specialist medical reports, 326
workplace-occurring hypoglycaemia, 325–326
encephalopathy, diabetic, 285, 302–303
endocrinopathies, and risk of severe hypoglycaemia, 74, 131, 330
endogenous insulin secretion absence affecting risk of severe hypoglycaemia, 72
effect of strict glycaemic control, 174
Epidemiology of Diabetes Interventions and Complications (EDIC) Study, 289
epinephrine (adrenaline) actions, 124, 142, 245, 276
defective response, 8, 69, 129, 130, 131, 132, 136
during sleep, 87, 88, 203
effect of alcohol, 106, 107
response to hypoglycaemia, 124, 275, 276
blood glucose threshold, 125
in children, 134, 202
effect of glycaemic control, 178
in older people, 241, 242
type 2 diabetes, 244, 245
euglycaemia, 1
mechanisms maintaining, 1–5
EURODIAB IDDM Complications Study, 64, 68, 73
exam-induced anxiety, and symptoms of hypoglycaemia, 326, 327
examinations [academic], 326–327
Exenatide, 255
exercise
benefits, 63, 312
counterregulatory response affected by, 63, 313
metabolic consequences, 312
safer time for, 314
exercise-induced hypoglycaemia, 63, 314
children, 200–201
delayed, 316
factors affecting, 313
management/prevention of, 206–207, 313–315
in type 2 diabetes, 246
fasting, metabolic pathways, 3–4
fatty acids
metabolic alterations, 3, 5, 9, 125
effect of alcohol, 104
fear of hypoglycaemia, 43–44, 74, 121, 172, 310–311
children, 206, 311
in pregnancy, 221
reasons for, 310
flushing (clinical sign), 17
fetus, effects of maternal hypoglycaemia, 231–233
folate/folic acid supplement, 229
frequency of hypoglycaemia, 51–60
asymptomatic hypoglycaemia, 55–57
in diabetic pregnancy, 219–222
factors affecting various studies, 51–52
mild hypoglycaemia, 52–55, 246
severe hypoglycaemia, 57–60, 122, 123, 198, 246
children, 194–195
pregnant women, 219, 220
in type 1 diabetes, 51–60
in type 2 diabetes, 246–256
and incretin mimetics, 255
and insulin, 253–256
and oral antidiabetic agents, 247–250
frequency of sudden death, 272
functional changes during hypoglycaemia, 18–20
gastric emptying, factors affecting, 20, 74, 102
gastrointestinal system, changes in blood flow during hypoglycaemia, 16–17, 17
gastroparesis diabeticorum, 74
 genetic predisposition to hypoglycaemia, 70–72, 174, 201
 genetically engineered insulin, 72, 161–162
 gestational diabetes, 220
  insulin management in, 228, 229
  screening for, 233
 glibenclamide, 247, 249, 251
 gliclazide, 249
  modified-release form, 249, 249
 glimepiride, 249, 249
 glipizide, 247, 249
glucagon
 actions, 2, 3, 124
response to hypoglycaemia, 8, 13, 15, 125, 127, 136
in children, 201
effect of alcohol, 104
impairment of, 127–129, 131, 132
in older people, 241, 242
type 2 diabetes, 243, 244, 244
in treatment of hypoglycaemia, 115, 207, 229
glucagon-like peptide 1 (GLP-1) analogues, 255
gluconeogenesis, 2, 3, 123
alcohol-induced suppression of, 62, 104
haemodynamic changes during hypoglycaemia, 15–16, 276
headache (symptom), 26, 30
children, 32, 196
in pregnancy, 221
heart rate change due to hypoglycaemia, 16, 19, 276, 277
as symptom, 26, 29, 31, 142, 143
hemiparesis, hypoglycaemic, 205, 290, 293
hepatic autoregulation, 9, 10, 123
defects, 130–131
effect of alcohol, 104–105, 106, 107, 130
in pregnant women, 221
Hypoglycaemia-Associated Autonomic Failure (HAAF), 69, 129, 130, 153–154, 244
risk-reduction strategies, 135
Hypoglycaemia Fear Survey (HFS), 43–44, 74, 311
hypoglycaemic hemiplegia, 205, 290, 293
hypoglycaemia unawareness, see impaired awareness of hypoglycaemia
Hypoglycaemia Anticipation, Awareness and Treatment Training (HAATT) programme, 34

INDEX

339
hypopituitarism, 74, 102, 130
hypothalamus, hormonal changes during hypoglycaemia, 13-14, 13
hypothermia, and hypoglycaemia, 317
iatrogenic causes of hypoglycaemia, 7
idiopathic epilepsy, misdiagnosis of, 291–293
illicit drinks, intoxication due to, 104
impaired awareness of hypoglycaemia and asymptomatic hypoglycaemia, 154–155
definition(s), 141, 145–146
effect of alcohol, 62, 104, 108
effect of duration of insulin therapy, 69, 147, 148
effect of strict glycaemic control, 147, 173, 176
mental performance affected by, 41, 146
methods of assessment, 145–147
nocturnal hypoglycaemia, 73, 88–89
pathogenesis, 149–161
in pregnant women, 221
prevalence, 147–149
as risk factor for severe hypoglycaemia, 69, 152, 161
treatment of, 163–165
in type 2 diabetes, 245–246
and undetected hypoglycaemia, 145
and worry, 44
incidence, see frequency of hypoglycaemia
incretin mimetics, and hypoglycaemia, 255
infants, see also children
developmental effects of maternal hypoglycaemia, 233–234
prevalence of severe hypoglycaemia, 194–195
inhaled insulin, 72, 254
injection site problems, 101, 135
insulin
actions, 2, 5, 7
24-hour profile in glucose homeostasis, 61
insulin analogues, 72, 94–95, 135
combined with metformin in type 2 diabetes, 254
and nocturnal hypoglycaemia, 94–95, 183
in children, 206
risk of hypoglycaemia affected by, 72, 174
in children, 199–200, 208–209
in pregnancy, 227
type 2 diabetes, 254
insulin delivery systems, see also continuous subcutaneous insulin infusion (CSII)
for children, 208
limitations, 86
for pregnant women, 226–229
risk factors affected by, 65, 101–102
insulin detemir, 95, 254
insulin glargine, 95, 208, 228, 254
insulin glulisine, 254
insulin-like growth factor 1 (IGF-1), glucagon response to hypoglycaemia affected by, 127
insulin lispro, 72, 95
children and adolescents, 208
in diabetic pregnancy, 227, 228
type 2 diabetes, 254
insulin requirements for children, 197
in pregnancy, 219
insulin resistance in adolescents, 197
in pregnancy, 218
insulin sensitivity, factors affecting, 102, 106, 181
intellectual activity, glucose consumption caused by, 327
intelligence quotient (IQ)
effect of hypoglycaemia, 288
in children, 205, 234, 286
intensive insulin therapy
cognitive dysfunction affected by, 41
contraindication for impaired awareness patients, 184
HbA1c levels, 65, 66, 67, 68, 147
and impaired awareness of hypoglycaemia, 147, 173
nocturnal hypoglycaemia affected by, 84, 85
pregnant women, 227
as risk factor for severe hypoglycaemia, 63–67, 102, 173–177, 285, 287, see also strict glycaemic control
in children and adolescents, 199–200, 208
risk of hyperinsulinaemia, 181
risk of ketosis, 179, 180
International Society for Paediatric and Adolescent Diabetologists (ISPAD)
classification of hypoglycaemia, 192, 193
guidelines, 206, 209
interstitial glucose concentration, relationship with blood glucose, 113, 114
interstitial glucose monitoring, 57, 112–114, see also continuous glucose monitoring systems
INDEX

limitations, 112, 113
use in detection of hypoglycaemia, 113–114, 121–122
interstitial hypoglycaemia, 112, 113
intravenous injection (in treatment of hypoglycaemia), 115–116
irritability (symptom), 43, 312
   in children, 32, 32, 33, 196, 327
isophane (NPH) insulin, 53, 54, 56, 57, 59, 66
   compared with insulin analogues, 95, 208, 254
   and nocturnal hypoglycaemia, 95, 163
   children and adolescents, 208
   in pregnancy, 227, 228
ketones
   metabolism, in brain, 6
   production, during fasting, 3
ketosis
   effect of strenuous exercise, 314
   as side effect of intensive insulin therapy, 179, 180
kidney, changes in blood flow during hypoglycaemia, 17, 18
   (kidney), contribution to gluconeogenesis, 2
labour, management of diabetes during, 230, 231
lactate, as glucose precursor, 2, 124, 125
language comprehension, effect of hypoglycaemia, 42
large goods vehicle (LGV) licences, 320, 324, 326
learning ability of children, effect of hypoglycaemia, 204–205, 286–287
   factors affecting, 40–41
   real-life implications, 41–43
metformin, frequency of hypoglycaemia, 247, 251
microvascular complications
   in diabetic pregnancy, 232
   effect of recurrent hypoglycaemia, 279
   effect of strict glycaemic control, 63, 171, 184, 197, 289
   frequency of severe hypoglycaemia affected by, 73–74
   reduction in prevalence, 122
mild hypoglycaemia
   attitudes to, 325
   definition(s), 50, 51, 112–114, 172, 192, 193, 246
   frequency, 52–55, 174
   management of, 114–115, 207
   minibus drivers, 320
   model for occurrence and avoidance of hypoglycaemia, 34
   moderate hypoglycaemia, 51, 172, 193
   moderators of hypoglycaemia
   type 1 diabetes, 103–111
   type 2 diabetes, 245–246
   monitoring, 111–114
   continuous systems, 57, 85, 112–114
liver
   changes in blood flow during hypoglycaemia, 17
   metabolic pathways, 2, 3, 4, 5
   long distance running, 316
   long QT syndrome, 274
   lorry drivers, 320, 327
management of hypoglycaemia, 114–116
   children, 207–209
   pregnant women, 230
marathon running, 316
maternal hypoglycaemia
   risks to fetus/infant, 232–234
   risks to mother, 231
memory impairment, hypoglycaemia-associated, 42–43, 111
mental arithmetic, effect of hypoglycaemia, 38
mental performance impairment, hypoglycaemia-impaired, 37–40, see also cognitive dysfunction
   in children, 204–205, 286–287
   factors affecting, 40–41
   real-life implications, 41–43
microvascular complications
   in diabetic pregnancy, 232
   effect of recurrent hypoglycaemia, 279
   effect of strict glycaemic control, 63, 171, 184, 197, 289
   frequency of severe hypoglycaemia affected by, 73–74
   reduction in prevalence, 122
mild hypoglycaemia
   attitudes to, 325
   definition(s), 50, 51, 112–114, 172, 192, 193, 246
   frequency, 52–55, 174
   management of, 114–115, 207
   minibus drivers, 320
   model for occurrence and avoidance of hypoglycaemia, 34
   moderate hypoglycaemia, 51, 172, 193
   moderators of hypoglycaemia
   type 1 diabetes, 103–111
   type 2 diabetes, 245–246
   monitoring, 111–114
   continuous systems, 57, 85, 112–114
lipolysis, 9, 123, 124
   alcohol-induced suppression of, 104
mood changes due to hypoglycaemia, 43, 314
  in examinations [academic], 326, 327
recovery from, 293
morbidity of hypoglycaemia, 255–256
type 2 diabetes, 256
mortality, 270
  risk factors, 267–272
motor skills, effect of hypoglycaemia, 38
multiple injection therapy
  children and adolescents, 199
  compared with CSII, 180, 181
  adolescents, 208
  and nocturnal hypoglycaemia, 84, 85
  and severe hypoglycaemia, 65, 181, 182
treatment of counterregulatory failure, 135
muscle
  changes in blood flow during hypoglycaemia, 17–18, 17
  metabolic pathways, 2, 3, 4, 5, 200
  sympathetic activity, 11–12
myocardial infarction, 279
myocardial ischaemia, 278–280
nateglinide, 250
nausea (symptom), 26, 30
  in children, 32, 196
neonates, risks of maternal hypoglycaemia, 232–234
nephropathy, 73, 279
  in diabetic pregnancy, 227, 232
  reduction in risk, 184
nervous system, see autonomic nervous system;
central nervous system (CNS)
nervousness (symptom), 26, 27, 29, 31
neuroendocrine activation during hypoglycaemia, 13–15
neuroglycopenic symptoms, 30, 31, 143–144, 196
  blood glucose threshold(s), 29, 50, 142, 151
  in children, 32, 196, 327
  compared with autonomic symptoms, 144
  confusion with alcohol intoxication, 62
  and detection of hypoglycaemia, 35–36, 142–143
  in exam situations, 326
  in older people, 240
neurological symptoms, in older people, 240
neurological syndromes,
  hypoglycaemia-induced, 289–290
neurophysiological dysfunction, blood glucose thresholds, 50, 142
neuropsychological deterioration due to severe hypoglycaemia
evidence for, 289–290
long-term manifestations, 295–296
transient manifestations, 290
nocturnal hypoglycaemia
  advice to patients, 276
  caffeine-associated reduction, 110
  causes, 74, 86–88
in children, 197
  and cognitive function, 204
  effect of exercise, 201, 209
clinical solutions, 92–95
  continuous subcutaneous insulin infusion, 95, 183
  dietary approach, 92–94, 208
  pharmaceutical interventions, 94
timing and type of insulin, 94–95, 163, 183, 206, 227, 228
consequences, 88–89
effect of exercise, 200, 315
epidemiology, 63, 76, 83–85
  frequency, 84
and impaired awareness, 74, 88–89, 200
  neurological consequences, 89
  prediction of, 90
  in children, 206
  in pregnancy, 219
  sudden death associated with, 83, 89, 267, 271–273, 274, 278
typical overnight glucose profiles, 85, 122
nocturnal insulin requirements, 95
  for children, 199
novel insulins, see insulin analogues
obese people, counterregulatory responses, 134
  observational data, effect of intensive therapy on severe hypoglycaemia, 66, 72
  ‘odd behaviour’ (symptom), 30, 31, 32, 43, 196
  in children, 32
  mistaken for alcohol inebriation, 327
offshore oil industry, employment in, 324
older people
  counterregulatory responses, 134, 241–242
  symptoms of hypoglycaemia, 33, 239–240, 240
  blood glucose thresholds, 240, 241
  unsuitability for strict glycaemic control, 184,
oral antidiabetic agents, see also alpha-glucosidase inhibitors; metformin,
frequency of hypoglycaemia;
sulphonylureas; thiazolidinediones
hypoglycaemic effects, 247–252
compared with insulin therapy, 251–253
oxygen, changes during hypoglycaemia, 13, 14–15
potassium levels, fall due to hypoglycaemia, 273, 276
‘pounding’ heart (symptom), 26, 29, 31, 142, 143
children, 32
older people, 240
in pregnancy, 221
proprandial glucose regulators, 249
hypoglycaemia, see also diabetic pregnancy
average age of mothers with diabetes, 217
frequency of hypoglycaemia, 219–222
lifestyle management in, 229
maternal complications due to diabetes, 230–231
metabolic changes during, 217–219
organisation of clinical care, 223–226
pre-conception care/counselling, 223
prevalence of hypoglycaemia
mild hypoglycaemia, 54, 246
nocturnal hypoglycaemia, 83, 193, 196
severe hypoglycaemia, 121, 198
in pregnancy, 220, 227
in type 2 diabetes, 253, 256
previous history of hypoglycaemia, see also antecedent hypoglycaemia
as risk factor, 64, 68, 69, 102, 157–160
in pregnancy, 221
and worry, 44
prison, management of diabetes in, 330–331
prison officer, as restricted occupation, 326
profound hypoglycaemia
counterregulatory responses, 134
hepatic autoregulation in, 9
increased cerebral blood flow in, 123
prolactin, changes during hypoglycaemia, 13, 14
prospective studies
compared with retrospective studies, 51–52, 172
mild hypoglycaemia, 53, 54–55
severe hypoglycaemia, 57, 58, 59
children, 194, 195, 286
type 2 diabetes, 248–249, 253, 254
protein snack, and nocturnal hypoglycaemia, 93
psychiatric disturbance/illness
effect of hypoglycaemia, 295
as risk factor for death, 58, 269
treatment of, 281
psychological consequences of hypoglycaemia, 311
INDEX

psychological factors, and risk of hypoglycaemia, 74
psychosocial manifestations of hypoglycaemia, 290, 310–312
reaction time, effect of hypoglycaemia, 38, 39
reactions to hypoglycaemia, 142, see also symptoms of hypoglycaemia
rebound hyperglycaemia, 90–91
clinical approach, 92
recreational activities, 317
regional blood flow, changes during hypoglycaemia, 16–18
renin, changes during hypoglycaemia, 15
repaglinide, 249
retinopathy in diabetic pregnancy, 227, 232
effect of hypoglycaemia, 73, 279
reduction in prevalence, 122
and strict glycaemic control, 184
retrospective studies compared with prospective studies, 51–52, 172
mild hypoglycaemia, 52, 53
severe hypoglycaemia, 57, 58, 59, 66
in children, 196, 205
type 2 diabetes, 248–249, 252, 254
risk factors for hypoglycaemia, 63–75, 101–103, 161, 173–177
in children, 197–202
for severe hypoglycaemia, 63–75, 149, 161, 173–177
for sudden death, 272–275
road traffic accidents (RTAs), hypoglycaemia-induced, 319–320
rosiglitazone, 247
school examinations, 326–327
schools, emergency treatment arrangements, 328
Scottish Diabetes in Pregnancy Study, 219, 220
severe hypoglycaemia definitions, 51, 51, 172, 193, 220, 246, 286
effect of intensive insulin therapy, 63–67, 173–177, 287
in children and adolescents, 199–200, 208
emergency service involvement, 58, 256–257
fear of future episodes, 74, 311, 312
frequency, 57–60, 196
children, 192–193
pregnant women, 219, 220
hospital referrals, 58, 60, 115, 116
management of, 115–116, 208
neuropsychological deterioration due to, 287–290
rates (1992–2002), 121, 123, 198
risk factors, 63–75, 149, 161, 173–177
sulphonylurea therapy, 247
type 2 diabetes
compared with type 1 diabetes, 256
insulin therapy, 253–256
oral antidiabetic agents, 247, 250
without warning symptoms, 65, 147, 162
and duration of insulin therapy, 69, 147
severe neuroglycopenia, blood glucose threshold, 142
shaking, see trembling (symptom)
shift work, 325–326
single photon emission [computed] tomography (SPE[C]T)
brain imaging study, 287
cerebral blood flow studies, 16, 297
skin, changes in blood flow during hypoglycaemia, 17
sleep, counterregulatory responses affected by, 73, 87–88, 203
sleep patterns
counterregulatory response affected by, 88, 203
effect of caffeine, 110
sleepiness (symptom), 26, 36
see also drowsiness (symptom)
smoking, risk of hypoglycaemia affected by, 75
socio-economic factors, risk of hypoglycaemia affected by, 74
somatostatin
action of, 8, 14, 15
changes during hypoglycaemia, 13, 15
Somogyi phenomenon, 90–91, 206
speech difficulty (symptom), 26, 30, 31, 36, 196
children, 32
older people, 240
spleen, changes in blood flow during hypoglycaemia, 17, 18
sporting activities, 315–317
Stockholm Diabetes Intervention Study (SDIS), 64, 65, 66, 289
strenuous exercise, 313, 314, 315, 317
strict glycaemic control, see also intensive insulin therapy
contraindications, 184
and fear of hypoglycaemia, 121, 310
and impaired awareness of hypoglycaemia, 147
mental performance affected by, 41
patients unsuitable for, 183–184
elderly, 182
young children, 185, 205
as risk factor for severe hypoglycaemia, 64,
67–68, 102, 172, 287
in children and adolescents, 197
risks, 171–190
side effects, 95, 171, 179–181
symptoms onset affected by, 41, 50, 150,
152, 155
Stroop test, effect of hypoglycaemia, 38
subcutaneous insulin injection, see also
continuous subcutaneous insulin infusion
(CSII)
factors affecting absorption, 101–102
sudden death, 269–274, see also deaths due to
hypoglycaemia and ‘Dead in bed’ Syndrome
frequency, 272
possible mechanisms, 269
risk factors, 274–278
syndromes in non-diabetic young people,
270–271
suicide
brain damage following attempt, 293
deaths due to, 271, 272
sulphonylureas, see also chlorpropamide;
glibenclamide; gliclazide; glimepiride;
glipizide; tolbutamide
drug interactions, 247, 250
hypoglycaemic effects, 245, 247–248, 250,
252
pharmacokinetics, 249
supine posture, counterregulatory responses
affected by, 87
sweating (symptom), 12, 18, 19, 26, 27, 30, 31,
36, 142, 143, 196
change with duration of insulin therapy, 148
children, 32, 32, 196
difficulty in interpreting, 38, 144
older people, 240
sympathetic nervous system, 10, 12
activation during hypoglycaemia, 10–12, 143
sympatho-adrenal responses to hypoglycaemia,
142, 143
deficient, 129, 132
and impaired awareness of hypoglycaemia,
151
symptoms of hypoglycaemia, 19, 25–37, 26,
142
blood glucose thresholds, 29, 50, 142,
149–152
effect of strict glycaemic control, 41, 50,
150, 178, 180
in older people, 240, 241
changes with duration of insulin therapy, 148
in children, 32–33, 196–197
classification, 33
correlation with blood glucose concentration,
28–29
detection of, 35–36
generation of, 34–35, 143
hierarchy affected by intensive insulin
therapy, 41, 179, 180
identifying, 19, 25–29, 26
incorrect interpretation, 28, 37
individuality, 27–28
tachycardia (symptom), 16, 19, 26, 29, 31
target blood glucose concentration
lower limit, 50, 114, 173, 192
recommended range(s), 185, 223
taxi drivers, 322, 326
tearfulness (symptom), in children, 32, 196
temperature, changes during hypoglycaemia,
19–20
tenseness (symptom), 27, 29, 43, 314, 329
teratogenic effects due to hypoglycaemia, 233
thiabutaline, and blood glucose levels, 94
therapeutic management (avoidance of
hypoglycaemia), 181–184
target blood glucose ranges, 182, 225
thiazolidinediones, 247
thinking slowed (symptom), 26, 31, 143
‘tingling’ (symptom), 26
tiredness (symptom), 26, 27, 30, 31, 43, 312,
327
tolbutamide
  glucagon response to hypoglycaemia affected
  by, 128
  pharmacokinetics, 249
INDEX

United Kingdom Prospective Diabetes Study (UKPDS), 247
universities, emergency treatment arrangements, 326
university examinations, 326–327
unsteadiness, as symptom in older people, 240
vascular complications, reduction by intensive insulin therapy, 171
vaso-vagal episode, misinterpretation of symptoms, 240
vasopressin, changes during hypoglycaemia, 13, 14–15
ventricular tachycardia (VT), 274, 277–278
ventromedial nucleus of hypothalamus (VMH), role in counterregulation, 10, 13, 125, 133
verbal fluency, effect of hypoglycaemia, 38
Veterans Affairs Cooperative Study in type 2 Diabetes (VA CSDM), 253–254, 254
Vildagliptin, 255
visual disturbances (symptom), 26, 31
children, 32, 196
older people, 240
visual processing, effect of hypoglycaemia, 42
vocational driving licences, 320
restrictions, 324

warmness (symptom), 30, 31, 32
warning symptoms, see symptoms of hypoglycaemia
weakness (symptom), 26, 29, 31
children, 196, 196
older people, 240
weight gain, and intensive insulin therapy, 171
working at heights, restrictions on, 324
worry about hypoglycaemia, 43–44, 83, 206, 313, see also fear of hypoglycaemia
in children, 206
nocturnal hypoglycaemia, 73, 312

unexplained deaths, 268–272,
see also sudden death
unhappiness during hypoglycaemia, 43, 312
United Kingdom Hypoglycaemia Study Group, 53–55, 252

unsteady, as symptom in older people, 240

unsteady, as symptom in older people, 240

type 1 diabetes
frequency of hypoglycaemia, 51–60
asymptomatic hypoglycaemia, 55–57
in children, 191–193
in diabetic pregnancy, 219–222
mild hypoglycaemia, 52–55
severe hypoglycaemia, 57–60, 122, 123, 198

type 2 diabetes
frequency of hypoglycaemia, 246–256
incretin mimetics, 255
insulin therapy, 253–256
oral antidiabetic agents, 247–250
impaired awareness of hypoglycaemia, 245–246
moderators of hypoglycaemia, 245–246
pregnant women, 220
risk of severe hypoglycaemia, 173, 177, 247
types of insulin, see also insulin analogues;
isophane (NPH) insulin
risk of hypoglycaemia affected by, 72, 174
in children, 199–200, 208–209

unexplained deaths, 268–272,
see also sudden death
unhappiness during hypoglycaemia, 43, 312
United Kingdom Hypoglycaemia Study Group, 53–55, 252

unsteady, as symptom in older people, 240

train drivers, 323, 324
trembling (symptom), 18, 19, 26, 27, 29, 30, 31, 142, 143, 196
change with duration of insulin therapy, 148
children, 32, 32, 196, 196, 197
older people, 240

travel arrangements, 322–323

transient ischaemic attacks (TIAs), misinterpretation of symptoms, 33, 240

trembling (symptom), 18, 19, 26, 27, 29, 30, 31, 142, 143, 196
change with duration of insulin therapy, 148
children, 32, 32, 196, 196, 197
older people, 240

trembling (symptom), 18, 19, 26, 27, 29, 30, 31, 142, 143, 196
change with duration of insulin therapy, 148
children, 32, 32, 196, 196, 197
older people, 240

triglycerides, metabolic alterations, 3, 5

truck drivers, 320, 326